Abstracts

Filters

Clear Filters
All Days Sun, Sep 27 Mon, Sep 28 Tue, Sep 29 Wed, Sep 30

Tuesday, September 29

2:45 PM - 2:55 PM ET

301 - Targeting TREM2+ Macrophages Overcomes Radiotherapy Resistance
Speaker: Wei, Shuhua, PhD - Peking University Third Hospital, Department of Radiation Oncology, Beijing
2:45 PM - 2:55 PM ET

307 - Quantifying Dose-Dependent Changes in Active Bone Marrow Using Multi-Energy CT and Fat Fraction MRI in Pelvic Radiotherapy
Speaker: Eckrich, Carolyn, MS, BS - University of Wisconsin, Madison, WI
2:45 PM - 2:55 PM ET

338 - Development and Validation of a Vendor-Neutral Backup and Recovery Software for Cyberattack Resiliency
Speaker: Liang, Danfu, PhD - Thomas Jefferson University, Philadelphia, PA
2:45 PM - 2:55 PM ET

Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB-IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study
Speaker: Filippi, Andrea, MD - Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Lombardia
2:45 PM - 2:55 PM ET

Impact of Photon-Counting CT on Organ Segmentation Quality
Speaker: Baum, Sebastian - Friedrich-Alexander University Erlangen-Nürnberg; Siemens Healthineers AG, Erlangen, Bavaria
2:45 PM - 2:55 PM ET

LBA 04 - Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB-IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study
Speaker: Filippi, Andrea, MD - Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Lombardia
2:55 PM - 3:05 PM ET

284 - Clinicogenomic Risk Stratification Identifies Metastatic Breast Cancer Patients at High Risk for Symptomatic Brain Metastases
Speaker: Pike, Luke, MD, DPhil - Memorial Sloan Kettering Cancer Center, New York, New York
2:55 PM - 3:05 PM ET

290 - Intratumoral-Peritumoral CT Radiomics with Machine Learning for Predicting Local Tumor Response after Radiotherapy in Non-Small Cell Lung Cancer
Speaker: Chen, Zhi - West China Longquan Hospital, Sichuan University; The First People’s Hospital of Longquanyi District, Chengdu, SiChuan
2:55 PM - 3:05 PM ET

296 - A Randomized Phase II Study of Hypofractionated Stereotactic Radiotherapy With Concurrent 5-FU/Capecitabine With or Without Zoledronic Acid in Locally Advanced Pancreatic Ductal Adenocarcinoma
Speaker: Lin, Chi, MD, PhD, MS - University of Nebraska Medical Center, Omaha, NE
2:55 PM - 3:05 PM ET

302 - Fluorescence Tracking Identifies Tumor-Draining Lymph Node as a Source of CD8 T Cells and Early Type I IFN-Mediated Activation after Tumor Radiation
Speaker: Friedman, David, PhD - Earle A. Chiles Research Institute, Portland, OR
2:55 PM - 3:05 PM ET

308 - Patterns of Nodal Failure after Cervical Cancer Chemoradiotherapy: The Role of Geometric Miss and Baseline Nodal Signal
Speaker: Su, Shiqin, PhD - University of Texas MD Anderson Cancer Center, Houston, TX
2:55 PM - 3:05 PM ET

339 - From Clinical Trials to Clinical Practice: An Analysis of Reproducibility and Transparency in High-Impact Radiation Oncology Trials
Speaker: Quirk, Sarah, PhD - Dana-Farber/Brigham and Women's Cancer Center, Boston, MA